Stocktoria
Zai Lab Ltd ZLAB
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-09-28
Zai Lab Ltd financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $460.2M | $399.0M | $266.7M | $215.0M | $144.3M | $49.0M | $13.0M | $129,000 | — | — |
| Gross profit | — | — | — | — | — | — | — | $85,862 | — | — |
| R&D expense | $220.9M | $234.5M | $265.9M | $286.4M | $573.3M | $222.7M | $142.2M | $120.3M | $39.3M | $32.1M |
| SG&A expense | $277.6M | $298.7M | $281.6M | $259.0M | $218.8M | $111.3M | $70.2M | $21.6M | $12.0M | $6.4M |
| Operating income | -$229.4M | -$282.1M | -$366.6M | -$404.4M | -$700.1M | -$301.8M | -$203.2M | -$141.8M | -$51.4M | -$38.5M |
| Interest expense | — | $2.3M | $0 | $0 | $0 | $181,000 | $293,000 | $40,000 | — | — |
| Income tax | -$2.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$175.5M | -$257.1M | -$334.6M | -$443.3M | -$704.5M | -$268.9M | -$195.1M | -$139.1M | -$50.4M | -$37.5M |
| EPS (diluted) | $-0.16 | $-0.26 | $-0.35 | $-0.46 | $-0.76 | $-0.35 | — | — | — | — |
| Operating cash flow | -$150.8M | -$214.9M | -$198.2M | -$367.6M | -$549.2M | -$216.1M | -$191.0M | -$97.5M | -$32.4M | -$32.2M |
| Free cash flow | -$158.9M | -$220.5M | -$205.4M | -$392.2M | -$567.5M | -$226.2M | -$197.0M | -$107.6M | -$41.5M | -$34.4M |
| Cash & equivalents | $679.6M | $449.7M | $790.2M | $1.0B | $964.1M | $442.1M | $75.9M | $63.0M | $229.7M | $83.9M |
| Inventory | $74.7M | $39.9M | $44.8M | $31.6M | $19.0M | $13.1M | $6.0M | $4,000 | — | — |
| Total assets | $1.2B | $1.2B | $1.0B | $1.2B | $1.6B | $1.3B | $355.2M | $302.0M | $249.6M | $88.9M |
| Total liabilities | $456.9M | $344.9M | $240.2M | $174.5M | $230.0M | $128.3M | $60.5M | $50.9M | $14.5M | $6.0M |
| Shareholders' equity | $715.5M | $840.9M | $796.1M | $1.0B | $1.4B | $1.2B | $294.7M | $251.1M | $235.2M | -$51.6M |
Growth · year-over-year · Revenue CAGR 221.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +15.3% | +49.6% | +24.0% | +49.0% | +194.8% | +277.0% | +9965.9% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.